Identification of Jun loss that promotes resistance to HDAC inhibitor Entinostat through Myc signaling in Luminal breast cancer
收藏NIAID Data Ecosystem2026-03-10 收录
官方服务：
资源简介：
This SuperSeries is composed of the SubSeries listed below. Refer to individual Series
应用场景：
创建时间：
2018-12-10
相关数据集
Table_2_Chemoresistance Transmission via Exosome-Transferred MMP14 in Pancreatic Cancer.docx
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies. Gemcitabine is the most commonly used chemotherapy for the treatment of PDAC, but the development of drug resistance still
NIAID Data Ecosystem90
DataSheet2_Exogenous proline enhances susceptibility of NSCLC to cisplatin via metabolic reprogramming and PLK1-mediated cell cycle arrest.xlsx
The occurrence of cisplatin resistance is still the main factor limiting the therapeutic effect of non-small cell lung cancer (NSCLC). It is urgent to elucidate the resistance mechanism and develop no
NIAID Data Ecosystem40
A feedforward loop between STAT1 and YAP1 stimulates lipid biosynthesis, accelerates tumor growth, and promotes chemotherapy resistance in mutant KRAS colorectal cancer.
In tumorous conditions, the transcription factor STAT1, traditionally recognized for its anti-tumor role in immunology, exhibits pro-survival characteristics, though the underlying mechanisms remain u
NIAID Data Ecosystem20
Gene expression profile of patient-derived head and neck squamous carcinoma cells subjected to different treatments.. Gene expression profile of patient-derived head and neck squamous carcinoma cells subjected to different treatments.
In order to investigate the mechanisms underlying response and resistance towards treatment in HNSCC, we used low passage in vitro HNSCC cultures from two patients, namely SJG26 and SJG17. Both cultur
NIAID Data Ecosystem70
Unveiling alterations of epigenetic modifications and chromatin architecture leading to lipid metabolic reprogramming during the evolutionary trastuzumab adaptation of HER2-positive breast cancer [Cut & Tag]. Unveiling alterations of epigenetic modifications and chromatin architecture leading to lipid metabolic reprogramming during the evolutionary trastuzumab adaptation of HER2-positive breast cancer [Cut & Tag]
Secondary trastuzumab resistance represents an evolutionary adaptation of HER2-positive breast cancer during anti-HER2 treatment. Most current studies have uncovered the alternations of HER2 and assoc
NIAID Data Ecosystem20
